biobБиобезопасность и БиотехнологияBiosafety and Biotechnology2707-72412957-5702Научно-исследовательский институт проблем биологической безопасности10.58318/2957-5702-2025-21-24-31biob-167Research ArticleСТАТЬИArticlesПЕРСПЕКТИВЫ И ЭФФЕКТИВНОСТЬ ИСПОЛЬЗОВАНИЯ ПРОДУКТОВ КРОВИ ДОМАШНИХ ЖИВОТНЫХ В МИКРОБИОЛОГИИ И МЕДИЦИНСКИХ ОТРАСЛЯХ (ЛИТЕРАТУРНЫЙ ОБЗОР)PROSPECTS AND EFFICIENCY OF USING DOMESTIC ANIMAL BLOOD PRODUCTS IN MICROBIOLOGY AND MEDICAL FIELDS (LITERATURE REVIEW)https://orcid.org/0009-0001-5786-6441ОлжабайА. Т.OlzhabayA. T.

Олжабай Аязбек Тойбекович 

Шымкент 

Shymkent

a.olzhabay@bioetica.kzhttps://orcid.org/0009-0003-3944-9825ШындаулетоваГ. С.ShyndauletovaG. S.

Шындаулетова Гульжан Сайлаубековна 

Шымкент 

Shymkent

office@bioetica.kzhttps://orcid.org/0009-0009-9941-2489МанапЕ.ManapE.

Манап Ерлан 

Шымкент 

Shymkent

erlanarda@gmail.comhttps://orcid.org/0009-0005-9537-9301ДжузеноваГ. Б.JuzenovaG. B.

Джузенова Гулия Бексултановна 

Шымкент

Shymkent

g.juzenova@daryn.kzТОО «Bioetica»Казахстан"Bioetica" LLPKazakhstanТОО «Дарын-2030»Казахстан"Daryn-2030" LLPKazakhstan2025020420250212431Copyright © Олжабай А.Т., Шындаулетова Г.С., Манап Е., Джузенова Г.Б., 20252025Олжабай А.Т., Шындаулетова Г.С., Манап Е., Джузенова Г.Б.Olzhabay A.T., Shyndauletova G.S., Manap E., Juzenova G.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.biosafety.kz/jour/article/view/167

Современная медицина и биофармацевтическая промышленность добились значительных успехов в эффективном использовании крови животных и ее компонентов. Однако в нашей стране динамичное развитие региона требует более активного внимания со стороны государственных органов и отраслевых организаций. Использование продуктов крови домашних животных, таких как овцы и лошади, открывает широкие возможности для производства питательных сред в микробиологии, разработки лекарственных средств и иммунобиологических препаратов. Кровь животных применяется при изготовлении кровяных и сывороточных агаров, что способствует улучшению качества диагностики в клинико-диагностических лабораториях. Международные нормативные акты, включая руководящие принципы ВОЗ и декларации ЮНЕСКО, ограничивают использование человеческой крови в коммерческих целях, что усиливает актуальность перехода к животным источникам. В Казахстане отсутствует стабильное производство крови животных для лабораторных нужд, что приводит к использованию просроченной или человеческой крови, создающей риски заражения и снижения точности диагностики. Рассмотрены примеры успешных отечественных разработок: компаниями «Экофарм Интернейшнл» и «Дарын-2030» налажен выпуск агаровых сред и антитоксических препаратов на основе лошадиной и овечьей крови. Настоящий обзор направлен на выявление перспектив, проблем и инновационных решений, связанных с применением продуктов крови животных, а также подчеркивает необходимость государственной поддержки и нормативного регулирования данной сферы в Республике Казахстан.

Modern medicine and the biopharmaceutical industry have achieved significant progress in the effective use of animal blood and its components. However, in our country, the dynamic development of the region requires greater attention from governmental bodies and sectoral organizations. The use of blood products derived from domestic animals, such as sheep and horses, presents broad opportunities for the production of microbiological culture media, as well as the development of medicinal products and immunobiological agents. Animal blood is utilized in the preparation of blood and serum agars, which contributes to improving the quality of diagnostics in clinical diagnostic laboratories. International regulatory acts, including the guidelines of the World Health Organization (WHO) and UNESCO declarations, restrict the commercial use of human blood, thus reinforcing the relevance of transitioning to animal-based sources. In Kazakhstan, the absence of stable domestic production of animal blood for laboratory purposes has led to the use of expired or human blood, posing infection risks and reducing diagnostic accuracy. The article highlights successful domestic developments, including the production of agar media and antitoxic preparations from horse and sheep blood by companies such as “EcoPharm International” and “Daryn-2030.” This review aims to identify the prospects, challenges, and innovative solutions related to the use of animal blood products, and emphasizes the need for governmental support and regulatory oversight of this sector in the Republic of Kazakhstan.

кровь овечьякровь лошадинаясыворотка лошадинаяпитательный агармеждународные нормативно-правовые актыsheep bloodhorse bloodhorse serumnutrient agarinternational regulatory actsReferencesByars T. D., Divers T. J. Clinical use of blood transfusions. – 1981.Byars T. D., Divers T. J. Clinical use of blood transfusions. – 1981.Durham A. E. Blood and plasma transfusion in the horse //Equine Veterinary Education. – 1996. – Т. 8. – №. 1. – С. 8-12.Durham A. E. Blood and plasma transfusion in the horse //Equine Veterinary Education. – 1996. – Т. 8. – №. 1. – С. 8-12.Cotter S. M. Clinical transfusion medicine //Advances in Veterinary Medicine. – 1991. – Т. 36. – С. 187-223.Cotter S. M. Clinical transfusion medicine //Advances in Veterinary Medicine. – 1991. – Т. 36. – С. 187-223.Vincent J. L. et al. Anemia and blood transfusion in critically ill patients //Jama. – 2002. – Т. 288. – №. 12. – С. 1499-1507.Vincent J. L. et al. Anemia and blood transfusion in critically ill patients //Jama. – 2002. – Т. 288. – №. 12. – С. 1499-1507.Goodnough L. T., Shander A. Blood management //Archives of pathology & laboratory medicine. – 2007. – Т. 131. – №. 5. – С. 695-701.Goodnough L. T., Shander A. Blood management //Archives of pathology & laboratory medicine. – 2007. – Т. 131. – №. 5. – С. 695-701.American Association of Blood Banks. Committee on Standards. Standards for blood banks and transfusion services. – The Committee, 1984. – Т. 160. – №. 2410.American Association of Blood Banks. Committee on Standards. Standards for blood banks and transfusion services. – The Committee, 1984. – Т. 160. – №. 2410.Goodnough L. T. Alternatives to allogeneic transfusion in patients with surgical anemia //Transfusion Therapy: Clinical Principles and Practice. – 2005. – С. 243-263.Goodnough L. T. Alternatives to allogeneic transfusion in patients with surgical anemia //Transfusion Therapy: Clinical Principles and Practice. – 2005. – С. 243-263.Chan T. et al. Consenting to blood: what do patients remember? //Transfusion Medicine. – 2005. – Т. 15. – №. 6. – С. 461-466.Chan T. et al. Consenting to blood: what do patients remember? //Transfusion Medicine. – 2005. – Т. 15. – №. 6. – С. 461-466.Morris D. D. Review of anemia in horses, part II: pathophysiologic mechanisms, specific diseases and treatment. – 1989.Morris D. D. Review of anemia in horses, part II: pathophysiologic mechanisms, specific diseases and treatment. – 1989.Stormont C. J. Blood groups in animals //Journal of the American Veterinary Medical Association. – 1982. – Т. 181. – №. 10. – С. 1120-1124.Stormont C. J. Blood groups in animals //Journal of the American Veterinary Medical Association. – 1982. – Т. 181. – №. 10. – С. 1120-1124.Wilde H. et al. Heterologous antisera and antivenins are essential biologicals: perspectives on a worldwide crisis //Annals of internal medicine. – 1996. – Т. 125. – №. 3. – С. 233-236.Wilde H. et al. Heterologous antisera and antivenins are essential biologicals: perspectives on a worldwide crisis //Annals of internal medicine. – 1996. – Т. 125. – №. 3. – С. 233-236.Dart R. C., McNally J. Efficacy, safety, and use of snake antivenoms in the United States //Annals of emergency medicine. – 2001. – Т. 37. – №. 2. – С. 181-188.Dart R. C., McNally J. Efficacy, safety, and use of snake antivenoms in the United States //Annals of emergency medicine. – 2001. – Т. 37. – №. 2. – С. 181-188.Mountain A., Adair J. R. Engineering antibodies for therapy //Biotechnology and Genetic Engineering Reviews. – 1992. – Т. 10. – №. 1. – С. 1-142.Mountain A., Adair J. R. Engineering antibodies for therapy //Biotechnology and Genetic Engineering Reviews. – 1992. – Т. 10. – №. 1. – С. 1-142.Lewis R. J., Garcia M. L. Therapeutic potential of venom peptides //Nature reviews drug discovery. – 2003. – Т. 2. – №. 10. – С. 790-802.Lewis R. J., Garcia M. L. Therapeutic potential of venom peptides //Nature reviews drug discovery. – 2003. – Т. 2. – №. 10. – С. 790-802.Galfrè G., Milstein C. [1] Preparation of monoclonal antibodies: Strategies and procedures. – 1981.Galfrè G., Milstein C. [1] Preparation of monoclonal antibodies: Strategies and procedures. – 1981.Harris W. J. Production of humanised monoclonal antibodies for in vivo imaging and therapy //Animal Cell Technology: Basic & Applied Aspects: Proceedings of the Sixth International Meeting of the Japanese Association for Animal Cell Technology, Nagoya, Japan, November 9–12, 1993. – Dordrecht : Springer Netherlands, 1995. – С. 53-61.Harris W. J. Production of humanised monoclonal antibodies for in vivo imaging and therapy //Animal Cell Technology: Basic & Applied Aspects: Proceedings of the Sixth International Meeting of the Japanese Association for Animal Cell Technology, Nagoya, Japan, November 9–12, 1993. – Dordrecht : Springer Netherlands, 1995. – С. 53-61.World Health Organization et al. World Health Organization (WHO) guiding principles on human cell, tissue and organ transplantation //World Health Organization: Geneva, Switzerland. – 2010.World Health Organization et al. World Health Organization (WHO) guiding principles on human cell, tissue and organ transplantation //World Health Organization: Geneva, Switzerland. – 2010.Hendriks A. Council of Europe-Convention for the protection of human rights and dignity of the human being with regard to the application of biology and medicine: Convention on human rights and biomedicine //Eur. J. Health L. – 1997. – Т. 4. – С. 89.Hendriks A. Council of Europe-Convention for the protection of human rights and dignity of the human being with regard to the application of biology and medicine: Convention on human rights and biomedicine //Eur. J. Health L. – 1997. – Т. 4. – С. 89.Lamotte K. R. United Nations Educational, Scientific and Cultural Organization (UNESCO): Universal Declaration on Cultural Diversity //International Legal Materials. – 2002. – Т. 41. – №. 1. – С. 57-62.Lamotte K. R. United Nations Educational, Scientific and Cultural Organization (UNESCO): Universal Declaration on Cultural Diversity //International Legal Materials. – 2002. – Т. 41. – №. 1. – С. 57-62.Lenk C., Beier K. Is the commercialisation of human tissue and body material forbidden in the countries of the European Union? //Journal of medical ethics. – 2012. – Т. 38. – №. 6. – С. 342-346.Lenk C., Beier K. Is the commercialisation of human tissue and body material forbidden in the countries of the European Union? //Journal of medical ethics. – 2012. – Т. 38. – №. 6. – С. 342-346.Russell F. M. et al. As a bacterial culture medium, citrated sheep blood agar is a practical alternative to citrated human blood agar in laboratories of developing countries //Journal of clinical microbiology. – 2006. – Т. 44. – №. 9. – С. 3346-3351.Russell F. M. et al. As a bacterial culture medium, citrated sheep blood agar is a practical alternative to citrated human blood agar in laboratories of developing countries //Journal of clinical microbiology. – 2006. – Т. 44. – №. 9. – С. 3346-3351.Sterzik B., FEHRENBACH* F. J. Reaction components influencing CAMP factor induced lysis //Microbiology. – 1985. – Т. 131. – №. 4. – С. 817-820.Sterzik B., FEHRENBACH* F. J. Reaction components influencing CAMP factor induced lysis //Microbiology. – 1985. – Т. 131. – №. 4. – С. 817-820.

The authors declare that there are no conflicts of interest present.